Definitive Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 results met or exceeded guidance, with revenue down 9% year-over-year and strong profitability. Strategic investments in AI, data, and digital activation are driving customer retention and new wins, while the Turbo platform is expected to support future growth.
-
Q1 2026 results were at or above guidance, with revenue down 6% year-over-year and strong margin expansion. Provider and diversified segments grew, offsetting life sciences declines, while AI and integration investments are expected to drive future growth.
-
A four-pillar strategy—data differentiation, integration, customer success, and innovation—has driven operational improvements, higher retention, and new growth opportunities. Recent investments in data quality, platform integration, and digital partnerships are positioning the business for renewed growth and margin stability in 2026.
Fiscal Year 2025
-
Q4 revenue and profitability exceeded guidance despite a 1% year-over-year revenue decline, with strong cash flow and margin expansion. Retention rates improved, claims data volumes were restored, and diversified/provider segments returned to growth, while 2026 guidance reflects continued top-line pressure but improved operational execution.
-
Q3 2025 results were at or above guidance, with $60M revenue (down 4% YoY) and strong cash flow. Enterprise customer count grew, renewal rates improved, and digital partnerships expanded, but life sciences upsell remains pressured. Cautious outlook continues amid macro and renewal headwinds.
-
Definitive Healthcare is executing a turnaround focused on data quality, integration, customer success, and innovation, supported by leadership changes and transparent communication. Despite macro headwinds in life sciences, operational improvements have stabilized renewals and positioned the company for future growth, with capital allocated to share buybacks and strategic investments.
-
Q2 2025 revenue and EBITDA exceeded guidance despite a 5% year-over-year revenue decline, with improved retention and strong professional services growth. Full-year guidance was raised, but macro pressures and Life Sciences downsell continue to weigh on outlook.
-
Q1 2025 revenue and adjusted EBITDA exceeded guidance despite a 7% year-over-year decline, driven by strong professional services and new logo wins. Retention rates stabilized but remain below targets, with ongoing macro uncertainty impacting renewals and sales cycles. FY 2025 guidance was tightened, with a continued focus on operational improvements and strategic investments.
-
The company is executing a turnaround focused on differentiated healthcare data, deeper integration, and improved customer retention. New data partnerships, operational restructuring, and cost initiatives are expected to drive margin and growth improvements, with full impact anticipated by late 2025 and into 2026.
-
Management is focused on unifying its platform, simplifying go-to-market processes, and leveraging partnerships to drive growth. Sales cycles have lengthened, but operational changes and data-driven resource allocation aim to improve revenue trajectory, with growth targeted for late 2025.
Fiscal Year 2024
-
Q4 revenue and adjusted EBITDA exceeded guidance despite a 6% year-over-year revenue decline, with elevated churn—mainly downsells—impacting life sciences. 2025 guidance anticipates continued revenue pressure in H1, with improvement expected in H2 as new partnerships and operational changes take effect.
-
Q3 revenue and adjusted EBITDA exceeded guidance despite a 4% year-over-year revenue decline, with strong cash flow and stable margins. Elevated churn and lower renewal rates, especially in life sciences, continue to pressure results, but operational improvements and a unified platform strategy aim to drive future growth. A $100 million share buyback and CFO transition were announced.
-
The company is evolving with a new CEO focused on customer engagement, platform unification, and operational efficiency. Growth is targeted through enterprise upsell, partnerships, and disciplined M&A, while improving churn and renewal rates remain top priorities.
-
Q2 2024 saw 5% revenue growth and 21% adjusted EBITDA growth, both above guidance, but macro headwinds and sales execution issues led to revised full-year guidance. The company is focusing on operational simplification, platform unification, and margin expansion, with strong cash flow supporting ongoing share repurchases.
-
The company is leveraging proprietary healthcare data and advanced analytics, including AI, to drive client value and expand self-service capabilities. Recent restructuring and product enhancements aim to deepen enterprise relationships and improve retention, while strong cash flow supports ongoing M&A and share buybacks.